Affymetrix Software User Manuals
... Subject to the Affymetrix terms and conditions that govern your use of Affymetrix products, Affymetrix grants you a nonexclusive, non-transferable, non-sublicensable license to use this Affymetrix product only in accordance with the manual and written instructions provided by Affymetrix. You underst ...
... Subject to the Affymetrix terms and conditions that govern your use of Affymetrix products, Affymetrix grants you a nonexclusive, non-transferable, non-sublicensable license to use this Affymetrix product only in accordance with the manual and written instructions provided by Affymetrix. You underst ...
HARVARD MEDICAL SCHOOL CURRICULUM VITAE Date Prepared
... photocoagulation. To assess the change in visual acuity and retinal thickness on OCT from baseline to month 8 and month 12 ...
... photocoagulation. To assess the change in visual acuity and retinal thickness on OCT from baseline to month 8 and month 12 ...
Recommendations for the Diagnosis and Treatment of the Acute Porphyrias
... developing erythrocytes. They are also classified clinically as acute or cutaneous on the basis of their major clinical manifestations. Of the 5 hepatic porphyrias, 4 characteristically present with acute attacks of neurologic manifestations— hence the designation acute porphyrias, a term that does ...
... developing erythrocytes. They are also classified clinically as acute or cutaneous on the basis of their major clinical manifestations. Of the 5 hepatic porphyrias, 4 characteristically present with acute attacks of neurologic manifestations— hence the designation acute porphyrias, a term that does ...
METHOTREXAT “EBEWE” 10 mg/ml and 100 mg/ml
... In severe, generalized, therapy-resistant psoriasis vulgaris including psoriatic arthritis and other autoimmunopathies: It is recommended that a test dose of 5-10 mg may be parenterally administered one week prior to initiation of therapy, in order to detect idiosyncratic adverse effects. The recomm ...
... In severe, generalized, therapy-resistant psoriasis vulgaris including psoriatic arthritis and other autoimmunopathies: It is recommended that a test dose of 5-10 mg may be parenterally administered one week prior to initiation of therapy, in order to detect idiosyncratic adverse effects. The recomm ...
Prior Authorization Drug Name Covered Uses Exclusion Criteria
... THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION. ...
... THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION. ...
Charles K. Wairuri , Jacquie E. van der Waals
... of a eukaryotic cell is an important step for successful infection, and also a prerequisite for ...
... of a eukaryotic cell is an important step for successful infection, and also a prerequisite for ...
Serpiginous Choroiditis: An Update
... case of serpiginous choroiditis following Herpes zoster. Priya et al 20 reported that two-thirds of aqueous humor samples from patients with serpiginous choroiditis in their study were positive for varicella zoster virus (VZV) or herpes simplex virus (HSV) using the polymerase chain reaction. Gupta ...
... case of serpiginous choroiditis following Herpes zoster. Priya et al 20 reported that two-thirds of aqueous humor samples from patients with serpiginous choroiditis in their study were positive for varicella zoster virus (VZV) or herpes simplex virus (HSV) using the polymerase chain reaction. Gupta ...
Managing chronic cough-Kelkar
... • Environmental Tobacco Smoke (ETS) exposure is associated with increased coughing illnesses and an imprtant contributing factor, ETS alone is not the sole etiology ...
... • Environmental Tobacco Smoke (ETS) exposure is associated with increased coughing illnesses and an imprtant contributing factor, ETS alone is not the sole etiology ...
Xq28 duplications
... member of each chromosome pair being inherited from each parent. Most cells of the human body have a total of 46 (23 pairs of) chromosomes. The egg and the sperm cells, however, have 23 unpaired chromosomes, so that when the egg and sperm join together at conception, the chromosomes pair up and the ...
... member of each chromosome pair being inherited from each parent. Most cells of the human body have a total of 46 (23 pairs of) chromosomes. The egg and the sperm cells, however, have 23 unpaired chromosomes, so that when the egg and sperm join together at conception, the chromosomes pair up and the ...
Wegener Granulomatosis (Granulomatosis with Polyangiitis
... virtually any organ can be involved. The spectrum and severity of the disease are heterogeneous, ranging from indolent disease involving only one site to fulminant, multiorgan vasculitis. The pathogenesis of WG has not been elucidated, but both cellular and humoral components are involved. Circulati ...
... virtually any organ can be involved. The spectrum and severity of the disease are heterogeneous, ranging from indolent disease involving only one site to fulminant, multiorgan vasculitis. The pathogenesis of WG has not been elucidated, but both cellular and humoral components are involved. Circulati ...
Disorders of Propionate and Methylmalonate Metabolism
... Formation of Propionate and Methylmalonate. Most of the propionic acid used by ruminant animals is formed by bacterial fermentation in the rumen.1 By contrast, nonruminant mammals derive most of their propionate from the catabolism of lipid and protein. As noted in Fig. 94-1, catabolism of the branc ...
... Formation of Propionate and Methylmalonate. Most of the propionic acid used by ruminant animals is formed by bacterial fermentation in the rumen.1 By contrast, nonruminant mammals derive most of their propionate from the catabolism of lipid and protein. As noted in Fig. 94-1, catabolism of the branc ...
Methadone maintenance therapy versus no opioid The Cochrane Library
... symptoms (Ward 1992), and thus reduces the need to use illegal heroin (Jaffe 1990). Methadone remains effective for approximately 24 hours, requiring a single daily dose rather than the more frequent administration of three to four times daily which occurs with the shorter-acting heroin (Jaffe 1990) ...
... symptoms (Ward 1992), and thus reduces the need to use illegal heroin (Jaffe 1990). Methadone remains effective for approximately 24 hours, requiring a single daily dose rather than the more frequent administration of three to four times daily which occurs with the shorter-acting heroin (Jaffe 1990) ...
A Physical Gene Map of the Bacteriophage P22 Late
... cleavage with EcoRI, BamHI, or EcoRI plus BamHI were cloned in Escherichia coli using the plasmid vector pBR322, and the resulting recombinant plasmids were introduced into Salmonella typhimurium. The genes present on a cloned fragment were identified by the ability of the hybrid plasmid to compleme ...
... cleavage with EcoRI, BamHI, or EcoRI plus BamHI were cloned in Escherichia coli using the plasmid vector pBR322, and the resulting recombinant plasmids were introduced into Salmonella typhimurium. The genes present on a cloned fragment were identified by the ability of the hybrid plasmid to compleme ...
Clinical and laboratory markers of disease activity and response to
... Clinical and laboratory markers of disease activity and response to therapy in South Africans with Rheumatoid Arthritis with disease duration less than two years ...
... Clinical and laboratory markers of disease activity and response to therapy in South Africans with Rheumatoid Arthritis with disease duration less than two years ...
What is p53
... oncogenic forms of human papillomavirus (HPV E6). In cells, p53 can associate with a 90-kD protein, identified as the product of the mdm-2 oncogene, which is amplified in some types of tumors. When bound to mdm-2, p53 can no longer function as an activator of transcription. p53 plays multiple roles ...
... oncogenic forms of human papillomavirus (HPV E6). In cells, p53 can associate with a 90-kD protein, identified as the product of the mdm-2 oncogene, which is amplified in some types of tumors. When bound to mdm-2, p53 can no longer function as an activator of transcription. p53 plays multiple roles ...
SVPaper050711
... presence of an ancestral insertion. Fifteen ancestral insertions (16%) had SNPs or short indels within their target site duplication, coincident with the insertion (Supplementary Table 8). Given their potential role in human disease30, we were interested to document the occurrence of recurrent SVs, ...
... presence of an ancestral insertion. Fifteen ancestral insertions (16%) had SNPs or short indels within their target site duplication, coincident with the insertion (Supplementary Table 8). Given their potential role in human disease30, we were interested to document the occurrence of recurrent SVs, ...
Genetics of Hemophilia
... the mutation on each gene is identical, as often is the case when the parents are related, the affected person is a homozygote. If the mutation from one parent is different from the mutation from the other parent, the affected person is a compound heterozygote (or double herterozygote). The parent o ...
... the mutation on each gene is identical, as often is the case when the parents are related, the affected person is a homozygote. If the mutation from one parent is different from the mutation from the other parent, the affected person is a compound heterozygote (or double herterozygote). The parent o ...
Properties of Mitotic and Meiotic Recombination in the
... (Liang et al., 1998). Saccharomyces cerevisiae strains that lack HR are very sensitive to DNA damaging agents such as X-rays (Resnick and Martin, 1976), and have a high rate of spontaneous chromosome loss (Song and Petes, 2012). HR is essential for cell survival of mammalian cells (Helleday, 2003). ...
... (Liang et al., 1998). Saccharomyces cerevisiae strains that lack HR are very sensitive to DNA damaging agents such as X-rays (Resnick and Martin, 1976), and have a high rate of spontaneous chromosome loss (Song and Petes, 2012). HR is essential for cell survival of mammalian cells (Helleday, 2003). ...
Intellectual property rights and innovation: Evidence from
... knowledge may rise more than proportionately with the stock. Celera genes appear to have accumulated lower levels of scientific knowledge during the time they were held with IP, and these temporarily lower levels of innovation may have led the accumulation of new scientific knowledge to be relativel ...
... knowledge may rise more than proportionately with the stock. Celera genes appear to have accumulated lower levels of scientific knowledge during the time they were held with IP, and these temporarily lower levels of innovation may have led the accumulation of new scientific knowledge to be relativel ...
Publication - The University of Texas Health Science Center at
... increased AIF-1 expression in the infiltrating cells within lesions [54–56]. A recent study demonstrated that AIF-1 promoted T-cell infiltration and induced the expression types I and III collagen and cytokines by normal dermal fibroblasts, providing additional evidence for a role of AIF-1 in scleroder ...
... increased AIF-1 expression in the infiltrating cells within lesions [54–56]. A recent study demonstrated that AIF-1 promoted T-cell infiltration and induced the expression types I and III collagen and cytokines by normal dermal fibroblasts, providing additional evidence for a role of AIF-1 in scleroder ...
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS)
... G allele is present at position -313. Genotyping of Mn-SOD -16 Ala → Val (-47 C to T) SNP (rs4880) was done by the method described by Manica-Cattani et al. (2012). A 110 bp exon 2 region containing the polymorphism site was amplified by using the following primers sequences: a 22-mer forward primer ...
... G allele is present at position -313. Genotyping of Mn-SOD -16 Ala → Val (-47 C to T) SNP (rs4880) was done by the method described by Manica-Cattani et al. (2012). A 110 bp exon 2 region containing the polymorphism site was amplified by using the following primers sequences: a 22-mer forward primer ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.